OncoCyte Corporation (OCX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joshua Riggs | President, CEO & Director | 504.63k | -- | 1983 |
| Mr. James Liu | Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer | 259.83k | -- | 1996 |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer | 409.27k | -- | -- |
| Mr. Peter Hong | VP, General Counsel & Secretary | -- | -- | -- |
| Mr. Yuh-Min Chiang Ph.D. | Senior Vice President of R&D and Product Development | -- | -- | -- |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations | -- | -- | -- |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | -- | -- | 1953 |
OncoCyte Corporation
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 43
Description
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Corporate Governance
Upcoming Events
August 7, 2024 at 8:00 PM UTC - August 12, 2024 at 8:00 PM UTC
OncoCyte Corporation Earnings Date